Summary
Johnson & Johnson (JNJ) filed an 8-K on November 13, 2017, detailing two significant events. Firstly, the company entered into a Second Supplemental Indenture on November 9, 2017, to amend redemption provisions for future securities issued under its 1987 Indenture. This action primarily affects the terms under which future debt can be redeemed, which is a standard corporate finance activity. More importantly for investors, on November 8, 2017, JNJ entered into an underwriting agreement to issue and sell a substantial aggregate principal amount of notes, totaling $4.5 billion. These notes are offered across various maturity dates and coupon rates, ranging from 1.950% for notes due in 2020 to 3.500% for notes due in 2048. The issuance and sale of these notes successfully closed on November 10, 2017. This debt issuance indicates JNJ's strategy to raise capital, likely for general corporate purposes or strategic initiatives, while managing its cost of debt.
Key Highlights
- 1Johnson & Johnson issued $4.5 billion in new senior notes across five different tranches with varying maturities (2020, 2025, 2028, 2038, 2048) and interest rates (ranging from 1.950% to 3.500%).
- 2The debt issuance closed on November 10, 2017, indicating successful placement of the new notes with investors.
- 3The company entered into a Second Supplemental Indenture to amend certain redemption provisions for securities issued after November 9, 2017.
- 4The notes were issued under Johnson & Johnson's existing Shelf Registration Statement on Form S-3.
- 5This debt offering represents a significant capital raising activity for the company.